BETA
Your AI-Trained Oncology Knowledge Connection!
Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Bexobrutideg Achieves High Objective Response Rate in Heavily Pretreated R/R CLL
Bexobrutideg, a novel BTK degrader, demonstrated preliminary clinical activity and a consistent safety profile in patients with relapsed/refractory chronic lymphocytic leukemia.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction
Ponatinib extended EFS and PFS in patients with newly diagnosed, Ph-positive acute lymphoblastic leukemia who did not achieve MRD negativity after induction.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
Dasatinib Misses Survival End Points in Core-Binding Factor AML
Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.
Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML
The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.